CSBio CSBio

X
[{"orgOrder":0,"company":"Heartseed","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","amount":"$598.0 million","upfrontCash":"$55.0 million","newsHeadline":"Heartseed and Novo Nordisk Enter Into Global Collaboration and Licence Agreement for Stem Cell-Based Therapy for Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"IND Enabling","country":"JAPAN","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Heartseed"},{"orgOrder":0,"company":"Heartseed","sponsor":"UTokyo Innovation Platform","pharmaFlowCategory":"D","amount":"$37.0 million","upfrontCash":"Undisclosed","newsHeadline":"Heartseed Raises $37 Million in Series C Funding to Accelerate Development of iPSC-derived Stem Cell Therapy for Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"IND Enabling","country":"JAPAN","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Heartseed"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Heartseed plans to use the new funds to accelerate the initiation of global clinical trial of our lead asset, HS-001 for HF as well as to confirm its proof of concept in Phase 1/2 LAPiS study in Japan.

            Lead Product(s): Allogeneic iPSC-derived Cardiomyocytes

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: HS-001

            Highest Development Status: IND Enabling Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: UTokyo Innovation Platform

            Deal Size: $37.0 million Upfront Cash: Undisclosed

            Deal Type: Series C Financing June 11, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            HS-001 is an investigational cell therapy using purified cardiomyocytes derived from induced pluripotent stem cells. Heartseed is planning to initiate a phase 1/2 clinical trial in Japan in the second half of 2021.

            Lead Product(s): Allogeneic iPSC-derived Cardiomyocytes

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: HS-001

            Highest Development Status: IND Enabling Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Novo Nordisk

            Deal Size: $598.0 million Upfront Cash: $55.0 million

            Deal Type: Collaboration June 01, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY